Amneal Pharmaceuticals, Inc.·4/A

Mar 27, 4:20 PM ET

Patel Chintu 4/A

4/A · Amneal Pharmaceuticals, Inc. · Filed Mar 27, 2026

Research Summary

AI-generated summary of this filing

Updated

Amneal (AMRX) Co-CEO Chintu Patel Receives Performance RSU Award

What Happened Chintu Patel, Co-CEO and director of Amneal Pharmaceuticals (AMRX), was granted a performance-based restricted stock unit (RSU) award representing up to 544,663 shares on March 2, 2026. The award is a derivative compensation grant (reported at $0.00 per share) and the filing on March 27, 2026 is an amendment correcting the original March 3, 2026 Form 4 to clarify that 100% of the grant consists of performance-based RSUs.

Key Details

  • Transaction date: March 2, 2026 (Period of Report). Amended Form 4 filed March 27, 2026; original Form 4 filed March 3, 2026.
  • Transaction type/code: Award/Acquisition (A) — derivative grant of performance-based RSUs.
  • Reported amount: 544,663 performance-based RSUs (reported as the maximum possible shares).
  • Price: $0.00 (no cash paid by the insider for the award).
  • Vesting/conditions: Units vest based on average closing price targets over a three-year performance period; payout may range from 0% to 200% of the target number. Any earned units vest in full on February 28, 2029.
  • Shares owned after transaction: Not disclosed in this filing.
  • Amendment note: This Form 4 corrects the Original Form 4, which had mistakenly reported non-performance RSUs; the entire grant is performance-based.

Context Performance-based RSUs are a form of compensation, contingent on meeting specified performance (stock-price) targets, and do not represent an immediate cash purchase or sale. Such grants are routine executive compensation and should not be interpreted alone as a direct bullish or bearish trading signal.

Insider Transaction Report

Form 4/AAmended
Period: 2026-03-02
Patel Chintu
DirectorCo-CEO
Transactions
  • Award

    Performance-Based Restricted Stock Units

    [F1][F2]
    2026-03-02+544,663544,663 total
    Class A Common Stock (544,663 underlying)
Footnotes (2)
  • [F1]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
  • [F2]Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.
Signature
/s/ Denis Butkovic, Attorney-in-Fact|2026-03-25

Documents

1 file
  • 4
    wk-form4a_1774642844.xml

    FORM 4/A